Traveling for Care?
Whether you're crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.
Research in cancer immunology at the Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University (JHU) has undergone a natural progression from basic laboratory studies of the host immune response to cancer to the clinical evaluation of immune-based cancer therapies. Many of these immune-based strategies to mobilize and augment the anti-tumor immune response were founded on the discoveries made by JHU investigators. Moreover, the application of immunotherapeutic strategies as an adjunct to cancer treatment across a wide range of malignancies and therapeutic settings has expanded dramatically over the past several years. The ability to carefully and reliably quantify the human immune response is critically important to assess the impact of any immunotherapeutic strategy.
While there is great diversity in the therapeutic modalities being studied, most areas, in fact, overlap strongly in their techniques and approaches to immunological analysis. Modern immunological techniques for characterizing and quantifying human immune responses are complex, and it is difficult for individual investigators to assemble all the techniques that may be most appropriate for a particular project. The Human Immunology Core Laboratory (HICL) was established in 2005 to provide SKCCC investigators the capacity to reliably monitor and quantify human immune responses using state-of-the-art immunologic assays. Thus, the specific goals of this CORE are to:
Julie Nauroth/Core Lab Director
Christopher Thoburn/Core Lab Manager